SOURCES SOUGHT
65 -- Nerve agent antidotes in auto-injectors
- Notice Date
- 12/28/2010
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- SPM2DP11R0101
- Archive Date
- 3/2/2011
- Point of Contact
- Neil Mcavinue, Phone: 215-737-3123
- E-Mail Address
-
Neil.Mcavinue@dla.mil
(Neil.Mcavinue@dla.mil)
- Small Business Set-Aside
- N/A
- Description
- *** BACKGROUND *** The Defense Logistics Agency - Troop Support supplies the military Services with nerve agent antidotes during peacetime and wartime. This is a Request for Information (RFI) on current manufacturing capabilities and new technology development for nerve agent antidotes in auto-injectors that might be used in wartime in response to chemical attacks. They could also be used in peacetime. This is not a request for proposals and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. All submitted information shall remain with the U.S. Government and will not be returned. *** OBJECTIVE *** The nerve agent antidote auto-injectors, hereinafter referred to as auto-injectors, are pressure activated devices suitable for intramuscular administration. The unit will contain active drug ingredients (e.g. atropine, pralidoxime, diazepam, etc.) for the purpose of countering the effects of nerve agent poisoning. In wartime, the need for auto-injectors may increase significantly. To meet an increased demand, the existing supply and baseline production capacity of auto-injector devices in the U.S. may need to expand. DLA Troop Support is requesting information on existing and planned manufacturing capabilities for auto-injectors. ***CURRENTLY MARKETED DEVICES*** If your firm currently markets an auto-injector device, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration (if applicable) d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW TECHNOLOGY/DEVICES UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture auto-injectors described in this RFI or that have technologies, devices or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this RFI will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for auto-injectors. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically in pdf format and emailed to neil.mcavinue@dla.mil
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/SPM2DP11R0101/listing.html)
- Record
- SN02351651-W 20101230/101228234032-bc3c889d0ad769e8fd640b72fe9dcb4d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |